The departure of the FDA commissioner after a turbulent one-year tenure leaves a vacuum at the top of a critical regulatory body, injecting uncertainty into multi-billion dollar decisions facing the pharmaceutical and biotech sectors.
Back
FDA Chief Makary Resigns After 1 Year, Raising Regulatory Questions
Food and Drug Administration Commissioner Marty Makary will resign Tuesday after just over a year in the role, following public reports of President Trump’s dissatisfaction and creating significant regulatory uncertainty for the pharmaceutical industry. Kyle Diamantis, the current FDA deputy commissioner for Food, will serve as acting commissioner.
“Marty’s a terrific guy but he’s going to go on and he’s going to lead a good life,” President Trump told reporters. “He was having some difficulty. You know, he’s a great doctor and he was having some difficulty.” The president declined to say whether he had asked for the resignation.
Makary’s brief tenure was marked by clashes on multiple fronts. His departure follows conflicts with the White House over the regulation of flavored vapes, with the FDA authorizing four new products last week despite Makary’s reported opposition. A White House official also confirmed that Health and Human Services Secretary Robert F. Kennedy Jr. had pushed for the resignation.
The leadership change injects immediate uncertainty into key FDA policy areas, from drug approvals to the regulation of e-cigarettes and abortion medication. For the pharmaceutical and biotech industries, the key question is who will be Makary's permanent successor and what their stance will be on regulatory policy, which could either accelerate or hinder new drug approvals.
The pressure on Makary was not limited to the executive branch. Anti-abortion groups, a key constituency for the administration, had publicly called for his ouster. They were angered by the FDA's decision under his leadership to approve a generic version of the abortion pill mifepristone and what they saw as a failure to roll back Biden-era rules allowing the pill to be mailed. Sen. Bill Cassidy (R-La.) had also previously criticized Makary over the agency's handling of the drug.
The resignation comes just one day before Makary was scheduled to testify before a Senate Appropriations subcommittee on the FDA's budget. His departure marks the third Senate-confirmed Trump administration official to leave their role this year, adding to a sense of instability in the administration's top health-policy ranks, which already lack a permanent CDC director and surgeon general.
This article is for informational purposes only and does not constitute investment advice.
[1] Trump says Makary is out as FDA commissioner, following industry and White House backlash[2] Marty Makary to resign as FDA commissioner after just one year[3] Trump's FDA boss resigning as admin taps next acting leader[4] FDA chief to depart after Trump signed off on ousting him[5] Trump's FDA commissioner, Dr. Marty Makary, to resign
